# US 2024/0002959 A1 · Rna separation and related techniques for determining viruses such as coronaviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002959 A1
- Document ID: US20240002959A1
- Status: Published application
- Kind: A1
- Application number: 18/240,748
- Filed: 2023-08-31
- Published: 2024-01-04
- Earliest claimed: 2021-03-17
- Assignees: Analiza, Inc.
- Applicants: Analiza, Inc.
- Inventors: Arnon Chait; Boris Y. Zaslavsky
- Web page: https://patentgrep.com/patent/US20240002959A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- G01N 33/587: {Nanoparticles}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G01N 33/523: {the element being adapted for a specific analyte}
- G01N 33/56983: {Viruses}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

## Claims

### Claim at position 1

1-59. (canceled)

### Claim 60

A method, comprising:
partitioning a biological fluid comprising a virus and free nucleic acid in an aqueous multi-phase partitioning system, wherein at least 70% of the free nucleic acid partitions in a first phase of the partitioning system; and
determining the virus within the partitioning system.

### Claim 61 (depends on 60)

The method of claim 60, comprising determining the virus in a second phase of the partitioning system.

### Claim 62 (depends on 60)

The method of claim 60, wherein determining the virus comprises determining the virus within the partitioning system in situ.

### Claim 63 (depends on 60)

The method of claim 60, wherein determining the virus comprises removing an aliquot from the partitioning system and determining the virus in the aliquot.

### Claim 64 (depends on 60)

The method of claim 60, comprising determining the virus using an agent comprising a signaling moiety and a virus-binding moiety.

### Claim 65 (depends on 64)

The method of claim 64, wherein the virus-binding moiety comprises an antibody.

### Claim 66 (depends on 64)

The method of claim 64, wherein the signaling moiety comprises gold nanoparticles.

### Claim 67 (depends on 66)

The method of claim 66, wherein the gold nanoparticles comprise a virus-binding moiety.

### Claim 68 (depends on 60)

The method of claim 60, comprising colorimetrically determining the virus within the partitioning system.

### Claim 69 (depends on 60)

The method of claim 60, further comprising releasing nucleic acid from the virus.

### Claim 70 (depends on 60)

The method of claim 60, wherein at least 95% of the free nucleic acid partitions in a first phase of the partitioning system.

### Claim 71 (depends on 60)

The method of claim 60, wherein the free nucleic acid arises from the virus.

### Claim 72 (depends on 60)

The method of claim 60, further comprising determining the free nucleic acid within the partitioning system.

### Claim 73 (depends on 72)

The method of claim 72, further comprising determining the free nucleic acid within the first phase of the partitioning system.

### Claim 74 (depends on 72)

The method of claim 72, wherein determining the free nucleic acid comprises sequencing the free nucleic acid.

### Claim 75 (depends on 74)

The method of claim 74, comprising sequencing the free nucleic acid using PCR.

### Claim 76 (depends on 72)

The method of claim 72, wherein determining the free nucleic acid comprises determining a concentration of the free nucleic acid.

### Claim 77 (depends on 76)

The method of claim 76, comprising determining a concentration of the free nucleic acid in the first phase of the partitioning system.

### Claim 78 (depends on 72)

The method of claim 72, wherein determining the free nucleic acid comprises determining the free nucleic acid within the partitioning system in situ.

### Claim 79 (depends on 72)

The method of claim 72, wherein determining the free nucleic acid comprises removing an aliquot from the partitioning system and determining the free nucleic acid in the aliquot.

### Claim 80 (depends on 60)

The method of claim 60, wherein the partitioning step occurs in less than 15 minutes.

### Claim 81 (depends on 60)

The method of claim 60, wherein the partitioning step occurs in less than 5 minutes.

### Claim 82 (depends on 60)

The method of claim 60, wherein the biological fluid arises from a subject suspected of being infected with a virus.

### Claim 83 (depends on 60)

The method of claim 60, wherein the biological fluid is blood.

### Claim 84 (depends on 60)

The method of claim 60, wherein the biological fluid is saliva.

### Claim 85 (depends on 60)

The method of claim 60, wherein the biological fluid is nasal fluid.

### Claim 86 (depends on 60)

The method of claim 60, wherein the subject is human.

### Claim 87 (depends on 60)

The method of claim 60, wherein the virus is a coronavirus.

### Claim 88 (depends on 60)

The method of claim 60, wherein the partitioning system consists of two phases.
